0000914190-20-000182.txt : 20200526 0000914190-20-000182.hdr.sgml : 20200526 20200526171329 ACCESSION NUMBER: 0000914190-20-000182 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200521 FILED AS OF DATE: 20200526 DATE AS OF CHANGE: 20200526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAUMGARTNER ROBERT V CENTRAL INDEX KEY: 0001258704 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 20911693 MAIL ADDRESS: STREET 1: 5775 WAYZATA BOULEVARD, SUITE 400 CITY: MINNEAPOLIS STATE: MN ZIP: 55416 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-05-21 0000842023 BIO-TECHNE Corp TECH 0001258704 BAUMGARTNER ROBERT V 5775 WAYZATA BOULEVARD, SUITE 400 MINNEAPOLIS MN 55416 1 0 0 0 Common Stock 2020-05-21 4 M 0 5000 70.35 A 14221 D Common Stock 2020-05-21 4 S 0 1300 265.3537 D 12921 D Common Stock 2020-05-21 4 S 0 1601 266.0706 D 11320 D Common Stock 2020-05-21 4 S 0 1974 267.3178 D 9346 D Common Stock 2020-05-21 4 S 0 125 267.9406 D 9221 D Stock Options (right to Buy) 70.35 2020-05-21 4 M 0 5000 0 D 2011-10-27 2021-10-26 Common Stock 5000 0 D Stock Options (right to buy) 66.90 2012-10-25 2022-10-24 Common Stock 5000 5000 D Stock Options (right to buy) 87.39 2013-10-31 2023-10-30 Common Stock 4000 4000 D Stock Options (right to buy) 91.78 2014-10-30 2024-10-30 Common Stock 4000 4000 D Stock Options (right to buy) 87.34 2016-10-29 2025-10-28 Common Stock 4260 4260 D Stock Options (right to buy) 101.19 2017-10-26 2026-10-26 Common Stock 3985 3985 D Stock Options (right to buy) 125.05 2018-10-25 2027-10-26 Common Stock 3125 3125 D Stock Options (right to buy) 179.84 2019-10-24 2028-10-25 Common Stock 1898 1898 D Stock Options (right to buy) 201.64 2029-10-24 Common Stock 2011 2011 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. /s/ Brenda S. Furlow as Attorney-in-Fact for Robert V. Baumgartner pursuant to Power of Attorney previously filed. 2020-05-26